Respiratory syncytial virus (RSV) is known to cause acute lung injury in the immunocompromised host, especially recipients of bone marrow allografts. Specific prognostic factors for the development of severe lifethreatening disease remain to be identified as does the optimum treatment of established disease. Over a 5-year period the incidence and outcome of RSV in BMT recipients was analysed retrospectively. Prognostic factors assessed included type of transplant, engraftment status at the time of infection, the presence of lower respiratory tract disease, viral genotype and treatment received. During the study period, 26 of 336 (6.3%) allogeneic stem-cell recipients were identified as having RSV. Five patients (19.2%) died as a direct result of RSV. One patient died secondary to an intracranial bleed with concomitant RSV. There were four patients with graft failure (two primary and two secondary) attributable to the presence of RSV, two of whom subsequently died of infections related to prolonged myelosuppression. The presence of lower respiratory tract infection and a poor overall outcome was the only statistically significant association. Unrelated donor transplants and AML as the underlying disease appeared to be associated with a poorer outcome. Engraftment status, viral genotype and RSV treatment received did not correlate with outcome. We conclude that future studies are required to identify early sensitive and reproducible prognostic factors of RSV in the immunocompromised host. The roles of intravenous and nebulised ribavirin need to be clarified by prospective controlled trials.
transplant (BMT). The course of disease in BMT patients appears to be age independent, with the characteristic signs of coryza and cough preceding the development of lower tract signs of tachypnoea, wheeze and need for supplemental oxygen. The development of pneumonia in these patients is often a pre-terminal event, with the subsequent chances of full recovery being extremely poor. 2 Respiratory syncytial virus is an enveloped RNA-containing paramyxovirus. It is mainly spread by the transfer of infected nasal secretions by hand. In the immunocompetent host, it primarily affects those under the age of 2 years accounting for the majority of admissions with acute respiratory distress during a seasonal epidemic. Fatal infections have been known to occur in this group of children, but more so in premature infants and those born with cardiac anomalies. Reinfections can occur throughout life but are seldom life-threatening in older children and adults. The fact that both adults and children can have recurrent infections during the same season, attests to the imperfect nature of the immunity and the infective power of the virus. 5 RSV has historically been divided serologically using monoclonal antibodies into two major groups, A and B. 6, 7 The nucleocapsid (N), glycoprotein (G) and small hydrophobic (SH) genes of RSV all exhibit sequence heterogeneity, the N gene being well conserved while the G gene is the most divergent. 8 Subsequent analysis of the sequence variability confirmed the division into groups A and B and has also been used to further subdivide these groups into genotypes. Restriction enzyme mapping of the N gene has allowed the classification of RSV isolates into six (NP1-NP6) genotypes. 9 Sequence analysis of the SH gene has been used to further subdivide subgroup A RSV isolates into four genotypes (SHL 1,3,4; SHL2; SHL5 and SHL6). G gene sequence variability has been shown to be closely related to these SHL genotypes and restriction enzyme mapping of the G gene can be used to assign subgroup A isolates to the SHL lineages. 10 Various groups have attempted to correlate RSV genotypes and serotypes with disease severity 11, 12 in an effort to explain the wide clinical spectrum of disease which is encountered with this virus. Fletcher and colleagues 12 found that 65% of infants infected with the SHL2 G genotype were more likely to suffer moderate to severe disease compared to the 30% of those with SHL6 who developed severe disease. No such work has as yet been done in immunocompromised patients with RSV.
There are a number of reports detailing experience with community-acquired respiratory virus infections in bone marrow transplant recipients. [13] [14] [15] [16] In one review, 13 RSV was found to be the responsible agent in 49% of cases, with just over half of these affecting the lower respiratory tract. Treatment options are either anti-viral, primarily using the virustatic agent, ribavirin or immunological, with the use of pooled or RSV specific immunoglobulin. It is not known if specific antiviral therapy affects outcome in this patient population.
This article discusses the experience with RSV infection on the BMT unit at The Royal Hospital for Sick Children, Bristol, UK, over a 5-year period. We primarily look at the overall outcome of RSV infection in the BMT recipient and then attempt to identify certain significant prognostic factors, including viral genotypes, which might affect outcome. It also describes the treatment that each patient received, its cost and how it affected their final outcome.
Methods

BMT patients
The BMT unit in Bristol is a specialist referral centre for unrelated donor (UD) bone marrow transplants. Between September 1987 and August 1998, 572 transplants were performed (313 unrelated donor, 161 sibling allogeneic and 98 autologous transplants). Two thirds of the patients transplanted were children (Ͻ16 years old). The majority of transplants were for haematological malignancies. 
Patient identification
Patients were identified from three separate sources. Firstly, we utilised the computerised database in the Virology Department at the Public Health Laboratory (PHLS), Bristol. This database spans the time period from July 1993 to August 1998. All positive RSV results, which cross-referenced to the BMT unit, were identified. Secondly, the BMT patient database was searched in order to identify any other patients not identified in the PHLS database. Finally, anecdotal accounts were taken from those who have worked in the unit since it originally opened (JMC, ABF, AO). Only the recipients of allograft transplants were studied. All the case notes on these identified patients were then retrospectively reviewed by the authors (AJMcC, HMK, CK, JM). The data extracted from each set of notes included: (1) Patient demographics (name, age, sex); (2) underlying disease, including remission status and treatment which the patient had received prior to transplant; (3) BMT protocol information (date and type of transplant, conditioning therapy and GVHD prophylaxis); (4) RSV information (date of acquisition, means of diagnosis, symptoms and signs, oxygen requirement, X-ray changes, neutrophil count at time of infection); (5) treatment received, including the need for ventilation; (6) outcome of RSV infection.
Patient population
Between the period from June 1993 to August 1998, there were 336 allogeneic transplants performed at the BMT unit, Bristol (248 unrelated and 88 sibling donor). In 26 of these patients (6.3%) RSV was identified. Sputum and/or cough swab specimens were the most common means of identifying the virus accounting for 12 out the 25 isolates. One patient was diagnosed serologically, seven patients had RSV identified from a bronchoalveolar lavage (BAL) specimen and six patients from nasopharyngeal aspirate (NPA) specimen. There was a preponderance of male patients (M:F = 4.2:1). The median age at bone marrow transplantation was 10.6 years (range 0.5 to 31.1 years). There were 17 unrelated transplants, of which eight were fully matched at HLA A, B, C, DR and DQ loci and nine had at least one antigen mismatch, and nine sibling allogeneic transplants (Table 1) .
BMT conditioning regimens, infection prophylaxis and definitions
Conditioning regimens used vary depending on the underlying disease. The patients identified in this study received either:
(1) cyclophosphamide 60 mg/kg once daily i.v. on days Ϫ6
and Ϫ5 (total dose 120 mg/kg) followed by total body irradiation (14.4 cGy) on days Ϫ3 to 0; or (2) busulphan 4 mg/kg p.o. in divided doses daily on days Ϫ8, Ϫ7, Ϫ6 and Ϫ5 (total dose 16 mg/kg, followed by cyclophosphamide 50 mg/kg once daily i.v. on days Ϫ4 to Ϫ1 (total dose 200 mg/kg).
All grafts from unrelated donors were T cell-depleted, both in vitro and in vivo using Campath Ig-M and Ig-G monoclonal antibodies, respectively. Sibling allogeneic grafts were T-cell replete.
Graft-versus-host (GVHD) prophylaxis was achieved using cyclosporin A (1.5 mg/kg twice a day started on day Ϫ1) with methotrexate (15 mg/m 2 (day 1) and 10 mg/m 2 (days 3, 6 and 11)) if there was a HLA mismatch between donor and recipient. All patients were started on itraconazole prophylaxis (dose 50-400 mg/day according to size) on day Ϫ8.
Patients at risk of CMV reactivation were given intravenous aciclovir (500 mg/m 2 three times a day) from day Ϫ4 to day ϩ30 and pooled intravenous immunoglobulin (IVIG), 200 mg/kg every 3 weeks. Those at low risk of developing CMV were given aciclovir at a dose of 5 mg/kg three times a day. All patients were commenced on a clean diet on day Ϫ4 which was continued until 30 days after discharge from isolation.
The day of engraftment was defined as the first of 3 consecutive days on which the absolute neutrophil count (ANC) was greater than or equal to 0.5 ϫ 10 9 /l or more. Primary graft failure was defined as never attaining a neutrophil count Ͼ0.5 ϫ 10 Ϫ9 /l. Secondary graft failure was defined as sustained loss of neutrophils Ͻ0.1 ϫ 10 Ϫ9 /l after achieving primary engraftment. A death was classified as being due to RSV if there was lower tract pulmonary involvement and this was felt to be the primary cause of death.
Diagnostic methods for detecting RSV
Direct immunofluorescence microscopy using RSV specific monoclonal antibodies and viral culture were employed to detect RSV in the appropriate specimens. These specimens were obtained by either NPA, BAL or sputum expectoration. NPAs were performed by instilling 5 ml of saline (0.9%) into the nasal passages and then suctioning through the nostrils with a paediatric mucous extractor (UNOPLAST Trachea Suction Set, Maersk Medical). BAL specimens from adult patients were obtained using a flexible bronchoscope (3.5 mm Pentax) and bronchoalveolar lavage using sterile saline. Sputa and cough swabs were procured in the usual manner. RSV was diagnosed in one patient using serological means with a four-fold rise in the RSV-specific IgG antibody titre detected in a symptomatic child before and after BMT. This child was low-risk for CMV and hence did not receive intravenous immunoglobulin at any stage after his transplant. It is, of course, possible that the rise in RSV-specific IgG was due to a blood transfusion, but this is an uncommon occurrence and an unlikely explanation.
During the annual RSV epidemic period (November to March) patients with possible RSV infection were identified by the presence of snuffles, cough, wheeze with or without a rise in temperature. Patients who were known to have had previous RSV infection, prior to transplant, were considered to be at a higher risk of RSV reactivation and hence would have been investigated at an earlier stage.
Assignment of RSV subgroup, N and G genotypes
Stored samples were available from 20 of 26 patients (77%) with RSV infection. In two of 20 available cases it was not possible to assign subtypes presumably due to sample deterioration. In a further case a subgroup was assigned but RT-PCR failed to amplify products that would enable us to assign N and G genotypes. Samples were analysed blindly by GST who was not aware of patient's clinical features, time cohort or outcome.
RNA extraction from clinical specimens and cDNA synthesis
RNA was extracted with Tri Reagent (Sigma-Aldrich, Poole, UK) according to the manufacturer's instructions and further purified by binding to silica in the presence of guanidinium thiocyanate. 26 cDNA was synthesised at 37°C for 1 h in a 25 l reaction containing 50 mm Tris-HCl (pH 8.3), 75 mm KCl, 3 mm MgCl 2 , 10 mm DTT, 250 ng random hexameric primers (Pharmacia, St Albans, UK), 1 mm of dNTPs (Promega, Southampton, UK) and 80 units of MML V reverse transcriptase (Promega).
Polymerase chain reaction and product analysis
PCR was performed in a 100 l reaction using either the RSV nucleocapsid gene or glycoprotein gene primers as previously described. 10 Each reaction contained 20 mm Tris-HCl (pH 8. 
Categorisation of RSV infection
In all patients a diagnosis of RSV infection was made by one or more of the following methods:
(1) Identification of RSV antigen by direct immunofluorescence in an nasopharyngeal aspirate specimen, bronchoalveolar lavage or cough plate; (2) a positive viral culture of the above samples; (3) a four-fold rise in RSV specific IgG antibody titre.
Patients were considered to have upper tract infection if they had coryzal symptoms and fever alone. Lower tract infection was defined by clinical means as the presence of chest signs (diffuse crackles and wheeze), and or significant hypoxaemia with oxygen saturations less than 90% in room air.
Radiological review
All chest X-rays were reviewed blindly by an independent radiologist (DG) who then assigned patients to upper or lower tract disease groups based on radiographic appearances alone. These results were then compared with the patient details. A retrospective assessment of the value of chest X-rays in RSV infection was then made.
Infection control policy
The Bristol BMT unit's infection control policy practices standard precautions for all patients undergoing bone marrow transplantation. All patients received their pre-transplant conditioning in open cubicles and were free to leave the unit during this period. Following BMT they were all nursed in positive pressure single rooms with air filtration by EU-8 grade filters and remained in protective isolation from day 0 until engraftment. Sterile gowns were worn by all visitors, including medical and nursing staff with hand washing before entering and leaving each cubicle. Each patient was limited to a maximum of four named visitors. Relatives and friends with any respiratory symptoms were requested to keep away until resolution of their symptoms. When RSV was isolated from a patient, in addition to the sterile gowns, all visitors wore gloves and plastic aprons, which were removed prior to them exiting from the cubicle. Face masks were not used in this unit. Wherever possible, all known RSV-infected patients were isolated from other patients when they attended outpatients.
Treatment of RSV positive patients
The unit's policy for the treatment of RSV positive patients has evolved over the study period. The various treatment options employed for these patients consist of: (1) Nebulised ribavirin (Virazid, ICN Pharmaceuticals, Basingstoke, UK; 20 mg/ml) administered as 6 g over an 18-h period via a small particle aerosol generator (SPAG) nebuliser; (2) intravenous ribavirin (Virazole, ICN Pharmaceuticals, 20 mg/ml) at a dose of 25 mg/kg/day loading dose followed by 15 mg/kg/day in three divided doses; (3) intravenous immunoglobulin at 0.2-0.4 g/kg/dose usually given two or three times a week. These options were used singly or in a combination of two or all three. During 1997-1998, a decision was made to evaluate the efficacy of concomitant intravenous and nebulised ribavirin.
Treatment was considered to be given late if it was administered more than 1 week following the onset of symptoms.
Statistics
The degree of significance was calculated retrospectively by chi-square analysis on the various variables studied.
Results
All infections occurred between November and March when RSV is prevalent in the United Kingdom. There was no specific seasonal variation noted in the prevalence or virulence of each infection period reviewed.
Overall outcome
There were five deaths (19.2%) directly attributable to RSV infection and one death due to an intracranial haemorrhage during an RSV infection. All deaths occurred in patients with lower respiratory tract disease.
There were four graft failures, two primary and two secondary, which could be related to the presence of RSV. All graft failures were in unrelated donor transplant recipients (three mismatched and one fully matched). Two of these patients (one primary and one secondary) had evidence of upper respiratory tract infection only. Two of these four patients with graft failure died of infection other than RSV due to persisting neutropenia. The other two were successfully retransplanted with a graft from another unrelated donor. One patient subsequently relapsed and died, while the other is alive and well.
Of the other 16 patients, two have subsequently relapsed and died of their original disease. One patient survives with Table 2 Clinical characteristics, X-ray findings and outcome Riba-neb = nebulised ribavirin; Riba-IV = intravenous ribavrin; IVIG = intravenous immunoglobulin; GF = graft failure; S = survived; D = dead.
Patient
chronic graft-versus-host disease with severe pulmonary involvement. The remaining 13 patients remain alive and well with a minimum of 6 months follow-up.
Site of infection and outcome
On clinical grounds alone, 11 patients had disease confined to the upper respiratory tract. There were no deaths due to RSV infection in this group but two patients suffered graft failure (one primary and one secondary). Fifteen patients had signs consistent with involvement of the lower respiratory tract, of whom six died. The association between LRTI and mortality reaches statistical significance (P = 0.04). Six of these patients had symptoms of upper respiratory involvement prior to progressing to lower tract disease. In one patient, BMT was deferred for 3 weeks at which stage he became RSV negative by direct immunofluorescence. He developed RSV again with lower tract signs during the course of his transplant and overcame the infection with the use of IVIG alone. Of the five other patients who appeared to progress, there were two deaths related to RSV and one graft failure temporally related to the RSV infection. Four out of five of these patients received treatment with ribavirin and/or IVIG. There was little correlation between those patients with clinical signs and symptoms of a lower respiratory infection and X-ray appearance. Of the 15 patients described with LRTI, only six had abnormal chest X-rays at diagnosis, four of whom died. One patient with clinical signs of an URTI alone, had X-ray changes consistent with infection. He survived the RSV infection, as did all others with clinical URTI alone ( Table 2) .
Engraftment status and outcome
The timing of RSV infection in relation to engraftment status did not appear to affect its attributable mortality (P = ෂ1). Nineteen of 26 patients became infected with RSV before engraftment, of whom three died. The four patients with graft failure, whether primary or secondary had preengraftment infection. Twelve patients who acquired infection pre-engraftment but for whom the infection was not associated with serious complications (ie significant myelosuppression or respiratory failure) were equally divided between upper and lower respiratory infection. Three patients developed infection prior to the start of conditioning. In two patients this was early enough to defer the transplant to a later date and both were RSV negative by immunofluorescence testing at the start of transplant, but became positive again during the early transplant course. Both patients developed lower respiratory infection but survived despite this.
Seven patients became infected in the post-engraftment period. The median number of days post transplant at the time of isolation of RSV was 111 days (range 45-1402 days). Two patients were more than 18 months post transplant. Both were still profoundly immunosuppressed, one having recently received donor lymphocyte infusions and the other receiving continuous chemotherapy because of resistant disease. One patient in this group died of a presumed intracerebral haemorrhage during an active RSV infection. There were two other deaths in this group directly attributable to RSV infection.
Treatment and outcome
Ribavirin administration by nebuliser, intravenous infusion or by both routes, did not significantly affect outcome of infection. Similarly, the use of IVIG failed to improve the clinical course of our patients.
Fifteen patients received treatment for their RSV infection. Five patients were treated with IVIG alone, three had nebulised ribavirin alone, three had intravenous ribavirin alone and four had both i.v. and nebulised ribavirin with IVIG. Treatment was given at a median of 7 days (range 1-22 days) from the onset of their symptoms and 1 day (range 0-16) from the isolation of the virus. One patient was receiving foscarnet and ganciclovir for a concomitant infection with cytomegalovirus. This patient did not receive specific anti-RSV therapy.
The five patients who received IVIG alone were divided into four late treatments of whom three had graft failure and one early treatment, who survived with graft intact. Ten patients received ribavirin in various combinations. Of the seven who were treated early, two died, four survived (two LRTI and two URTI) with graft intact and one developed graft failure. Of the three patients who received treatment late, all for LRTI, one died and two survived.
Pharmacoeconomics of treatment with ribavirin
Of the 26 patients with RSV studied, 10 received treatment with ribavirin. Of these 10 patients, three received ribavirin by inhalation only, three patients received ribavirin by injection only and four patients received a combination of the two. The cost of using ribavirin for the treatment of RSV can be found in Table 3 .
Transplant type, underlying disease and outcome
Unrelated donor bone marrow transplants were significantly associated with more mortality (P = 0.05-0.02) from RSV than were the sibling donor transplants.
Seventeen patients received unrelated grafts of whom five died of, or with RSV and four patients developed graft failure. There were nine sibling grafts from which there was one death and no graft failures.
RSV subtypes and outcome
Details of the RSV subtypes (A or B) and genotypes (N and G) in 17 of 26 patients are shown in Table 2 . Subgroup B was marginally more common (10 vs 7). NP types were mainly confined to type 3 (10 patients) and type 4 (five patients) with two patients having type 2. G genotypes could only be assigned to subgroup A RSV isolates as the primers used do not amplify the G gene of subgroup B. Of the eight patients with subgroup A, three had G type SHL2, two had SHL6 and two had SHL 1,3,4 and one patient could not be analysed.
In general, numbers are too small to correlate subtyping with clinical features or outcome. Cases that were temporally clustered tended to belong to the same A or B subgroup (Table 4) . The three patients diagnosed in January and February 1995 were NP4, SHL2 but this does not necessarily help us in deciding how the disease was acquired. Sequencing would be required to determine if the virus in the three patients was the same. Being subgroup A or B did not correlate with survival but numbers are too small to reliably detect an association. The two patients with graft failure were both infected with subgroup B, NP3 type viruses but these cases were temporally clustered. It has been suggested previously that the SHL2 G genotype correlated with more severe disease; all three patients with this type in our series survived and only one of three had lower tract disease.
Discussion
Community acquired respiratory viral infections occur in 15-30% of BMT patients every year, with one third to one half of these due to RSV. 13, 17 RSV infection occurred in 6% of our patients, over a 5-year period. We grant that this figure of 6% may an underestimate of the true incidence of RSV; all infection studies are potentially susceptible to a certain degree of underestimation. In approximately 20% Table 3 The cost of using ribavirin in the treatment of RSV infections of these patients, death was directly attributable to the virus. In a further small proportion of cases, the presence of the virus may have contributed to graft failure, leading to profound neutropenia and death due to infection. The only major factor affecting outcome was the presence, on clinical grounds alone, of lower respiratory tract disease. No other factor assessed reached statistical significance. Morbidity was more commonly seen in recipients of unrelated donor transplants. Rapid diagnosis of RSV in BMT patients is essential. Nasopharyngeal aspiration and nasal washings can be uncomfortable procedures, but in children, are regarded as a good source for the rapid detection of RSV by antigen detection. In adult patients, this procedure does not give an adequate cell yield to make a sensitive diagnosis and in these patients bronchoalveolar lavage is more appropriate. 18 Radiological changes are non-specific in the setting of BMT where a number of other opportunistic infections may give rise to similar findings. CT scans of the chest might be more sensitive, but we are not aware of any data concerning their use in BMT patients with RSV infections.
Infection with RSV has a variable clinical course and the impact of treatment may only become clear in large randomised studies. The outcome of patients with severe pneumonia is universally poor, especially when assisted ventilation is necessary and it would seem logical to target patients with early disease for therapy. However, until more specific early prognostic factors can be identified, this policy will mean treating many patients not destined to develop severe complications. We attempted to identify some of these prognostic factors in this review. The only factor which reached prognostic significance was the presence of lower respiratory tract disease based on clinical grounds alone. Unrelated donor transplant recipients tended to do worse, as did those with AML as the underlying disease. Although neither reached statistical significance, because of our small sample size, they may be considered as factors worth evaluating in future studies. Other factors such as conditioning therapy, engraftment status and treatment received all failed to affect overall outcome. Due to the small sample size we were unable to confirm previous findings which report that selected genotypes may be associated with more severe disease. 12 However, the temporal distribution of the RSV genotypes that were isolated in this study was in agreement with what is known about the circulation of RSV during winter epidemics. Studies on successive epidemics at a single location have reported that several genotypes co-circulate during each epidemic, the proportion of which vary, and that the genotypes which predominate in one epidemic tend to become less significant in the next epidemic. 9, 11, 19, 20 We are unable to determine if specific treatment for RSV affected outcome. Only 15 of 26 patients received anti-RSV therapy, with 10 of 15 receiving ribavirin. Although the median time between virus isolation and treatment was 1 day, a median of 1 week passed between the development of symptoms and start of treatment. This delay appears to be due to failure of NPA to detect the viral antigen in older patients and the necessity to resort to bronchoscopy and bronchoalveolar lavage. This delay may have reduced the efficacy of specific treatment in controlling the infection. The role of ribavirin in the immunocompetent host with RSV induced-bronchiolitis remains uncertain. 21, 22 It may have a more established role in premature infants or those with congenital heart defects. 23, 24 There are to date no prospective randomised studies that enable us to evaluate its role in immunocompromised patients. The use of ribavirin in our unit was neither controlled nor randomised and thus we are unable to come to any conclusion with regard to its efficacy in dealing with this infection. The identification of prognostic factors in future studies would help in deciding which patients would most benefit from the early introduction of ribavirin. In our hands, we found the use of ribavirin represented a significant additional expense of £3614 for the average of 11 days treatment. The cost-benefit analysis was particularly unfavourable for those patients who received the i.v. preparation alone. The poor outcome of these patients may be attributed to the fact that they did not receive it until they were, or just about to be, ventilated. The development of respiratory failure in this group of patients is considered a pre-morbid condition, unresponsive to any currently available therapy.
Combination therapy with aerosolised ribavirin and intravenous immunoglobulin for the treatment of RSV infection in BMT patients has been reported, 25 with early diagnosis and treatment being predictive of good outcome. Specific RSV-Ig has not yet been shown to have a proven role in this disease.
In conclusion, RSV is a significant cause of mortality in the immunocompromised host. Over a 5-year period, 6% of our BMT patients acquired the virus either peri-or posttransplant, of whom five died. Graft failure was noted in four patients and may be related to RSV infection. The only prognostic factor that reached statistical significance was the presence of lower respiratory tract disease. Future studies are required to identify early, sensitive prognostic factors so that appropriate treatment can be given in time to prevent the development of lower respiratory tract disease in this group of patients. The role of ribavirin or other antiviral agents requires clarification. Due to the lack of proven efficacy in this field, randomised placebo-controlled trials would appear to be the best method of deciding whether the additional expense of ribavirin is justified.
